(Q84602740)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Update on biologic therapy in the management of axial spondyloarthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Update on Biologic Therapy in the Management of Axial Spondyloarthritis (English)

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

author name string

Frank Heldmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Friedrich Dybowski

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Ertan Saracbasi-Zender

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Claas Fendler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Jürgen Braun

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20665135

12 June 2024

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

8 February 2020

http://www.current-reports.com/1523-3774/12/325

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20665135

http://link.springer.com/content/pdf/10.1007/s11926-010-0125-y.pdf

12 June 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

http://link.springer.com/article/10.1007/s11926-010-0125-y/fulltext.html

12 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

http://link.springer.com/content/pdf/10.1007/s11926-010-0125-y

12 June 2024

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

Current Rheumatology Reports

12 June 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

325-331

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20665135%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11926-010-0125-y

8 February 2020

exact match

0 references

cites work

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab

1 reference

12 December 2020

Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry

1 reference

12 December 2020

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes

1 reference

12 December 2020

Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis

1 reference

12 December 2020

Remission in ankylosing spondylitis.

1 reference

12 December 2020

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period

1 reference

12 December 2020

Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis.

1 reference

12 December 2020

Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept

1 reference

12 December 2020

Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis

1 reference

12 December 2020

Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis

1 reference

12 December 2020

Biological therapies in the spondyloarthritides--the current state

1 reference

12 December 2020

Infliximab treatment of severe ankylosing spondylitis: one-year followup

1 reference

12 December 2020

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

1 reference

12 December 2020

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria

1 reference

12 December 2020

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

1 reference

12 December 2020

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

1 reference

12 December 2020

Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective

1 reference

12 December 2020

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

1 reference

12 December 2020

Infliximab treatment in ankylosing spondylitis: an observational study

1 reference

12 December 2020

Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis

1 reference

12 December 2020

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

1 reference

12 December 2020

Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis

1 reference

12 December 2020

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)

1 reference

12 December 2020

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents

1 reference

12 December 2020

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

1 reference

12 December 2020

Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation

1 reference

12 December 2020

Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.

1 reference

12 December 2020

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

12 December 2020

Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment

1 reference

12 December 2020

Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Société de Rhumatologie de l'Ouest

1 reference

12 December 2020

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis

1 reference

12 December 2020

Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial

1 reference

12 December 2020

Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study

1 reference

12 December 2020

Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

1 reference

12 December 2020

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

1 reference

12 December 2020

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

1 reference

12 December 2020

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

12 December 2020

Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two

1 reference

12 December 2020

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

1 reference

12 December 2020

Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab

1 reference

12 December 2020

Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup

1 reference

12 December 2020

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study

1 reference

12 December 2020

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis

1 reference

12 December 2020

European biologicals registers: methodology, selected results and perspectives

1 reference

12 December 2020

Low dose of infliximab is inadequate in most patients with spondylarthropathies.

1 reference

12 December 2020

Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years

1 reference

12 December 2020

Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis

1 reference

12 December 2020

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

1 reference

12 December 2020

Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.

1 reference

12 December 2020

Ankylosing spondylitis

1 reference

12 December 2020

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

12 December 2020

The natural course of radiographic progression in ankylosing spondylitis--evidence for major individual variations in a large proportion of patients

1 reference

12 December 2020

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

1 reference

12 December 2020

Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change

1 reference

12 December 2020

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab

1 reference

12 December 2020

The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.

1 reference

12 December 2020

Adalimumab is effective and well tolerated in treating patients with ankylosing spondylitis who have advanced spinal fusion

1 reference

12 December 2020

Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis

1 reference

12 December 2020

Expression of cathepsin K and matrix metalloproteinase 1 indicate persistent osteodestructive activity in long-standing ankylosing spondylitis

1 reference

12 December 2020

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

1 reference

12 December 2020

Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup

1 reference

12 December 2020

A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis

1 reference

12 December 2020

Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study

1 reference

12 December 2020

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.

1 reference

12 December 2020

Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis

1 reference

12 December 2020

3

26

2622

A Saraux

1999

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

15

33

558

S Keeling

2006

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

21

34

510

X Baraliakos

2007

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

Annals of the Rheumatic Diseases

12 June 2024

25

67

346

JC Davis Jr

2008

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

54

7

1109

W Mau

1988

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

55

29

118

J Brandt

2002

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y

12 June 2024

56

31

531

J Brandt

2004

1 reference

https://api.crossref.org/works/10.1007/S11926-010-0125-Y